September is Prostate Cancer Awareness Month
This month, “We Wear Blue” for all men facing this challenging diagnosis. Through compassionate care and clinical expertise, we foster a supportive community for men and their families where they are empowered to discuss their health journey openly through ongoing, personalized support. Join us as “We Wear Blue,” stand together, and show our commitment to improving the lives of men affected by prostate cancer.
See Why “We Wear Blue” in Support of Prostate Cancer Patients
John – Wearing Blue for Prostate Cancer
Meet John. He’s an Onco360 patient and advocate for PSA screenings in his community.
“We Wear Blue” for ZERO Prostate Cancer’s MENtor Program
For Prostate Cancer Awareness Month, we have donated $18,000 to ZERO prostate Cancer’s MENtor Program to provide peer-to-peer support for 500 prostate cancer patients.
ZERO knows that a prostate cancer diagnosis can be a difficult and emotional experience, and this Program provides MENtees caring and thoughtful MENtors to offer their experiences and insights.
Find out more about ZERO’s MENtor program.
“We Wear Blue” and Support Our Prostate Cancer Patients
• As a specialty pharmacy 100% focused on cancer, we will act as your advocate with your physician, insurance company, and others involved in your treatment.
• Our Team of OncoAdvocates® explores funding options for qualified patients quickly with our proprietary
Funding FastTrack program.
• Timing is crucial when it comes to cancer treatment. Our goal, without prior authorization or funding issues, is to have your medication delivered within 3-4 days. We even provide complimentary overnight shipping to your doorstep.
• Our innovative and personalized Prostate Medication Therapy Management Programs provide 1-on-1 support to make sure you understand your medications, their dosage, and any potential side effects. Our clinicians are on call 24/7 if you have any issues at 877.662.6633.
Currently, our prostate cancer patients’
average copay is $24
97% of our prostate cancer patients
paid less than $50 for their last dispense
Last year, Onco360 sourced over
$132 million in funding for prostate
cancer patients
Prostate Cancer Statistics
• According to the American Cancer Society, other than skin cancer, prostate cancer is the most common cancer in American men. In 2024, It is estimated that about 299,000 new cases will be diagnosed.1
• Almost all prostate cancers are adenocarcinomas, which is a cancer that forms in a gland and can spread to other areas of the body. Other types of cancer that can start in the prostate include:
- Small cell carcinomas
- Neuroendocrine tumors (other than small cell carcinomas)
- Transitional cell carcinomas
- Sarcomas
Risk Factors
- Age – about 6 cases in 10 diagnosed are 65 or older, with an average age of 67
- Race/Ethnicity – African American men and Caribbean men of African ancestry are at a higher risk
- Geography – most common in North America, northwestern Europe, Australia, and on Caribbean islands
- Family history – Family history can increase your risk. For example, having a father or brother with prostate cancer can more than double the risk.
Onco360 dispenses these medications to treat prostate cancer.
Casodex® (bicalutamide)
Deltasone (prednisone)
Erleada® (apalutamide)
Firmagon® (degarelix)
Jevtana® (cabazitaxel)
Keytruda® (pembrolizumab)
Lupron® (leuprolide)
Medrol (methylprednisolone)
Nilandron® (nilutamide)
Novantrone® (mitoxantrone)
Nubeqa® (darolutamide)
Paraplatin® (carboplatin)
Platinol® (cisplatin)
Taxotere® (doxetaxel)
Toposar® (etoposide)
Trelstar® (triptorelin)
Xgeva (denosumab)
Xtandi® (enzalutamide)
Yonsa® (abiraterone acetate, micronized)
Zoladex® (goserelin)
Zometa (zoledronic acid)
Zytiga® (abiraterone acetate)
****This list is a small portion of the comprehensive medications Onco360 can provide.
If you are a provider and would like to refer to Onco360, click below
Helpful Resources:
1What is Prostate Cancer. Accessed August 6, 2024. https://www.cancer.org/cancer/types/prostate-cancer/about/what-is-prostate-cancer.html https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html